US Allows First Emergency Use of Covid-19 Antibody Drug

Health officials in the United States have allowed emergency use of the first antibody-drug to help the immune system fight Covid-19, reports AP.

This is an experimental approach against the coronavirus in the country. More than 238,000 Americans have been killed due to the virus.

The U.S. Food and Drug Administration on Monday cleared the experimental drug from Eli Lilly. The therapy is still in test to establish its safety and effectiveness. It is similar to a treatment that President Donald Trump took after coronavirus infection last month.

The drug, called bamlanivimab, may help clear the coronavirus sooner, suggests the early results. Additionally, it possibly cut hospitalizations in people with mild to moderate Covid-19, the AP report said.

Earlier, the U.S. government reached an agreement to buy and supply the drug.

The new drug therapy offers a promising new approach to prevent serious disease and death from Coronavirus infection. According to the experts, the infused drugs could serve as a therapeutic bridge to help manage the virus until vaccines are widely available, AP reports.

Read Also: Prominent Singer Kumar Sanu Tests Positive for Covid-19

The laboratory-made drug is versions of antibodies and blood proteins. Which the body creates to help target and eliminate foreign infections. The new therapies are concentrated versions of the antibodies proving most effective against the virus in patients.


5 Home Business Pitfalls and How to Avoid Them?

Working and running a business from your home can...

Do not Make These 5 Carpet Cleaning Mistakes while Cleaning Your Carpet 

A carpet is one of the essential components of...

Cyber and Data Security: This is How To Keep Your Business Safe?

In the last year, up to 39% of businesses in...

Everything You Wanted to Know about Evolution of the Stars

The stars, which are gaseous spheres that emit vast...

OnePlus 9RT Review: Key Features, Specifications and Price

OnePlus built its brand on low-cost flagships, and even...